Alexander Anatolyevich Zakharenko

Alexander Anatolyevich Zakharenko

Auto-generated profile, based on publicly available information

Alexander Anatolyevich Zakharenko

First Pavlov State Medical University of St. Petersburg

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2023 in Nephrology (Saint-Petersburg)
Verified
Journal Article
Open access
PDF file
KSK. S. Suprunovich
K. S. Suprunovich
IPI. A. Paltyshev
I. A. Paltyshev
AZA. A. Zakharenko
A. A. Zakharenko
VDVladimir Dobronravov
Vladimir Dobronravov
The risk of acute kidney injury (AKI) in cancer patients is much higher than in the general population. Common causes of AKI in this group of patients are toxicity of chemotherapy com ponents and water-electrolyte imbalances. The risks of AKI increase significantly if the patient has a history of chronic kidney disease of any etiology. Risk assessment and correction, prevention and treatment of acute and chronic renal dysfunction are the standard tasks of onconephrology The clinical case of acute kidney disease described here illustrates the main mechanisms and factors of organ dysfunction and its outcomes as a con­ sequence of colorectal cancer treatment. The necessity of multidisciplinary cooperation in determining the management and treatm ent tactics of such patients is shown, that is essential for the long-term prognosis.

19 June 2022 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
KOK. A. Oganyan
K. A. Oganyan
AMAram Ashotovich Musaelyan
Aram Ashotovich Musaelyan
MKM. A. Kotikova
M. A. Kotikova
SLSergey V. Lapin
Sergey V. Lapin
VNVladimir Nazarov
Vladimir Nazarov
SOS. V. Orlov
S. V. Orlov
Introduction. The emergence of new markers that determine the choice of therapy for metastatic colorectal cancer (CRC) has led to an increase in overall survival. The optimal treatment tactics now take into account both clinical and molecular-genetic characteristics of the tumor.Aim. Investigation of the features of the KRAS, NRAS and BRAF mutations and amplification of the HER2 gene depending on microsatellite instability (MSI) in CRC.Materials and methods. The study included 400 patients with CRC. MSI, BRAF V600E mutation, mutations in the KRAS and NRAS genes was identified to them. MSI was determined by fragment analysis, and mutations in the KRAS, NRAS, BRAF genes by realtime PCR. HER2 amplification was determined in 100 patients with a negative RAS/BRAF. NTRK translocations were determined in all patients with MSI. Data on preoperative levels of CEA and CA19-9 were obtained from 185 patients.Results and discussion. The prevalence of MSI was 6.8%. The prevalence of KRAS, NRAS, BRAF mutations in CRC with MSI was 66.7%, and in CRC with MSS - 52.3%. In patients with MSI, the level of CEA was lower than in MSS (p = 0.0061). The overall prevalence of KRAS and NRAS mutations was 45% and 2.5%. The overall prevalence of the BRAF V600E mutation was 5.8% and was more common in MSI-positive tumors (p < 0.0001). Regardless of MSI, BRAF-positive tumors were characterized by right-sided localization (p < 0.0001), category T3-4 (p = 0.013), lymph node involvement (p = 0.004), carcinomatosis (p = 0.046), high levels of CA19-9 (p = 0.014). HER2 amplification was found in 7% of wild-type RAS/BRAF cases and was associated with rectal cancer (p = 0.044), category T3-4 (p = 0.041), and distant metastases (p = 0.038). HER2 amplifications and NTRK translocations were not detected in cases with MSI.Conclusion. MSI-positive CRC had a higher prevalence of mutations in major genes. CRC with the BRAF V600E mutation and HER2 amplification had aggressive clinical and morphological parameters.

15 May 2021 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
AMAram Ashotovich Musaelyan
Aram Ashotovich Musaelyan
VNVladimir Nazarov
Vladimir Nazarov
ABA. S. Budnikova
A. S. Budnikova
SLSergey V. Lapin
Sergey V. Lapin
SVS. L. Vorobyev
S. L. Vorobyev
SOS. V. Orlov
S. V. Orlov
Background. Microsatellites are short tandem nucleotide repeats, the change in length of which plays a key roles in the pathogenesis of various malignant neoplasms. This change is called microsatellite instability. It is caused by aberrations in the genes of DNA mismatch repair system. Tumors with microsatellite instability are a special subtype regardless of location and are characterized by high sensitivity to immune checkpoint inhibitors.Objective – determination of characteristic clinical and morphological patterns of tumors of various localizations with microsatellite instability.Materials and methods. The study included 512 patients with malignant tumors of different localizations. Of these, 359 patients were diagnosed with colorectal cancer, 57 with uterine body cancer, and 57 with stomach cancer. Determination of the status of microsatellite instability was performed by a PCR-based method using 5 mononucleotide markers: BAT-25, BAT-26, NR-21, NR-24, NR-27.Results. The prevalence of microsatellite instability in colorectal cancer, uterine neoplasm and gastric cancer was 6.4; 22.8 and 1.75 %, respectively. Patients with MSI-positive colorectal cancer are characterized by yonger age (p = 0.023), right-sided localization of the tumor (p 0.0001), presence of multiple primary tumors (p = 0.0299), poorly differentiation (p = 0.0025), mucinous component (p 0.0001), tumor-infiltrating lymphocytes (p 0.0001) and Crohn-like reaction (p = 0.0006). Patients with uterine neoplasms with microsatellite instability are characterized by the presence of endometrial adenocarcinoma (p = 0.047), as well as the presence of tumor-infiltrating lymphocytes (p = 0.0022) and cribriform growth (p = 0.0011).Conclusion. A common pattern for colorectal cancer and uterine neoplasms is the presence of tumor-infiltrating lymphocytes. Certain clinical and morphological features of tumors of these localizations will more accurately identify candidates for microsatellite instability status determination for further immunotherapy.

28 June 2022 in Grekov's Bulletin of Surgery
Verified
Journal Article
Open access
PDF file
EKE. V. Kiseleva
E. V. Kiseleva
ФНФ. С. Нефедьев
Ф. С. Нефедьев
AZA. A. Zaharenko
A. A. Zaharenko
MZM. I. Zaraiski
M. I. Zaraiski
Screening allows detecting not only tumors in the early stages, but also precancerous diseases. Over the past decades, due to the introduction and implementation of screening programs in many Western countries, there has been a gradual decrease in morbidity and mortality. Several screening tests have been developed to detect and prevent colorectal cancer (CRC). These tests differ in technology, cost and object of study. At present, the stool occult blood test and fibrocolonoscopy are mainly used to detect CRC. However, the search for new non-invasive and reliable markers with high sensitivity and specificity and suitable for the early diagnosis of CRC remains an urgent task. Due to the ability of microRNAs to be present outside the formations in various biological fluids of the body and to be determined using the polymerase chain reaction (PCR), the detection of microRNAs has shown significant promise in the diagnosis and prognosis of CRC.

1 October 2025 in Siberian journal of oncology
Verified
Journal Article
Open access
PDF file
IVI. V. Vervekin
I. V. Vervekin
AZA. A. Zakharenko
A. A. Zakharenko
The aim of the study was to evaluate of the efficacy and safety of neoadjuvant chemotherapy (nCT) with mFOLFIRINOX regimen for treating patients with resectable pancreatic cancer. Material and Methods. Since 2020, a prospective phase II clinical trial that tests the effectiveness of mFOLFIRINOX chemotherapy followed by radical surgery compared to surgery followed by chemotherapy has been conducted at Pavlov First Saint Petersburg State Medical University for patients with resectable pancreatic cancer. A preliminary analysis of the immediate treatment outcomes has been presented. As of September 2024, 80 patients were included in the study (standard treatment group: n=41, nCT group: n=39). Patients in the standard treatment group underwent radical surgery followed by mFOLFIRINOX aCT (oxaliplatin 85 mg/m2 IV for 120 min, irinotecan 150 mg/m2 IV for 90 min, calcium folinate 400 mg/m2 IV for 120 min, 5-fluorouracil 2400 mg/m2 IV infusion for 46 hours every 2 weeks) for 12 cycles; patients in the experimental treatment group underwent tumor verification at the first stage (endosonography-guided fine-needle aspiration biopsy with subsequent cytological examination or percutaneous biopsy), after which 6 cycles of mFOLFIRINOX nCT and radical surgery followed by mFOLFIRINOX aCT were performed for 6 cycles. The immediate surgical outcomes, complications and mortality rates were assessed. Results. A statistically significant superiority of the nCT group over the standard treatment group was revealed in the following indicators: frequency of portal and/or superior mesenteric vein resections – 10.2 vs 21.9 % (OR 0.44, 95 % CI [0.149–1.329] p=0.04), R0 resections – 88.5 vs 73.2 % (OR 0.6, 95 % CI [0.118–0.909], p=0.03), lymphovascular invasion – 52.6 vs 14.8 % (OR 0.28, 95 % CI [0.108–0.730] p=0.05), microvascular invasion – 55.2 vs 11.1 % (OR 0.26, 95 % CI [0.1–0.669] p=0.01), perineural invasion – 65.7 vs 37 % (OR 0.56, 95 % CI [0.327–0.969] p=0.01), frequency of negative lymph node status (pN0) – 73.1 vs 41.5 % (OR 0.61, 95 % CI [0.331–0.969] p=0.009). Conclusion. nCT is a promising and safe method that can improve immediate treatment outcomes in patients with resectable pancreatic cancer.

4 July 2022 in Grekov's Bulletin of Surgery
Verified
Journal Article
Open access
PDF file
AZA. A. Zakharenko
A. A. Zakharenko
AKA. H. Khamid
A. H. Khamid
ASA. A. Svechkova
A. A. Svechkova
MBM. A. Belyaev
M. A. Belyaev
KVK. N. Vovin
K. N. Vovin
APA. V. Prudnikov
A. V. Prudnikov
Применение эндоскопической фотодинамической терапии в комплексном лечении злокачественных новообразований желудка (обзор литературы)